U.S. markets close in 1 hour 25 minutes
  • S&P 500

    3,904.65
    -7.09 (-0.18%)
     
  • Dow 30

    31,467.70
    -32.98 (-0.10%)
     
  • Nasdaq

    11,541.47
    -66.15 (-0.57%)
     
  • Russell 2000

    1,776.84
    +11.10 (+0.63%)
     
  • Crude Oil

    109.55
    +1.93 (+1.79%)
     
  • Gold

    1,825.80
    -4.50 (-0.25%)
     
  • Silver

    21.17
    +0.04 (+0.19%)
     
  • EUR/USD

    1.0594
    +0.0036 (+0.34%)
     
  • 10-Yr Bond

    3.2040
    +0.0790 (+2.53%)
     
  • GBP/USD

    1.2280
    +0.0010 (+0.08%)
     
  • USD/JPY

    135.4560
    +0.2860 (+0.21%)
     
  • BTC-USD

    20,891.91
    -301.46 (-1.42%)
     
  • CMC Crypto 200

    455.68
    -6.11 (-1.32%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., June 07, 2022--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease.

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 879247. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

About Aldeyra

Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006078/en/

Contacts

Investors & Media:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: (857) 383-2409
ALDX@investorrelations.com